Table 1

Review eligibility criteria based on study population, concept, context and types of studies

Review criteriaInclusionExclusion
PopulationParticipants of adults aged over 18 years with chronic condition using care obtained from any secondary care services regardless of outcomes.Evaluations of new technologies that do not include pharmacist involvement (eg, evaluating the feasibility of integrating laboratory testing methods into interventions).
ConceptThe characteristics of pharmacist-led interventions and outcome assessments used to measure the effectiveness of these interventions on quality use of medication and patient safety.Evaluations of new technologies included in the pharmacist-led interventions (eg, WhatsApp reminders for increased adherence).
Any study conducted to evaluate the impact of pharmacist-led interventions collecting health-related clinical, humanistic and economic outcomes.Studies involving exclusively pharmacy technicians, community pharmacists and pharmacy students.
Interventions performed individually or within a multidisciplinary team.
ContextSecondary care settings including hospital inpatient, outpatient clinics and community health centres in the community, where the interventions or activities are still conducted by hospital pharmacists considering these settings as part of secondary care.Community pharmacies (primary care).
Types of studiesPrimary (original) empirical research studies and full-text articles.Review studies, guidelines and organisational recommendations, protocols, editorials, lectures, editor letters, books, book chapters. Articles of which we cannot obtain the full text such as abstracts presented at conferences.
Any study design that reports on quantitative or qualitative types (eg, randomised controlled trials, quasi-experimental, cohort studies, cross-sectional studies and case reports).
Retrospective or prospective studies identifying the impact of pharmacist-led interventions will be considered. If a study includes both a hospital pharmacist and a technician, it can be included.
Articles written in English.Articles written in other languages than English.
Grey literature sources, such as International Pharmaceutical Abstracts and International Pharmaceutical Federation website.